BioSpace News Archive

Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today announced that four abstracts have been accepted for presentation, including a late-breaker, at the upcoming 8 th Joint Congress of the American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Res

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that Sarah Boyce , Avidity’s President and CEO, will participate in a fireside chat at the 2020 Wells Fargo Virtual Healthcare Conference

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that management will participate in two upcoming investor conferences. John Tucker, Chief Executive Officer, is scheduled to present at the virtual H.C. Wainwright

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (“Regulus”), today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will present at the Wells Fargo Virtual Healthcare Conference on Wednesd

Anthem, Inc. (NYSE: ANTM) has named Jeffrey D. Alter Executive Vice President, IngenioRx and Anthem Health Solutions, effective September 8, 2020. Mr. Alter will serve as a member of the company’s Senior Leadership Team and report directly to Gail K. Boudreaux, President and Chief Executive Officer, Anthem. “Jeff is a respect

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the following upcoming investor conferences

Multi-center, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of BIO89-100 administered weekly or every two weeks for 8 weeks

New study has important patient safety implications, as shortening dialysis timeline reduces reliance on riskier vascular access procedures

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression, and other central nervous system (CNS) disorders,

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, today announced that management will participate in the following virtual healthcare investor conferences: Citi’s 15th Annual BioPharma Virtual Conference on Thursday, September 10, 2020. H.C. Wainwright 22nd A